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Predicting clinical response in people
at ultra-high risk of psychosis: a
systematic and quantitative review
Andrea Mechelli1, a.mechelli@kcl.ac.uk, Diana Prata2,3, Charles Kefford1 and Shitij Kapur1
People at ultra-high risk (UHR) of psychosis have 30% chance of developing the illness within two
years. A range of pharmacological and psychosocial interventions are now available but there is great
individual variation in clinical response. Here we examine the evidence for clinically applicable
predictors of clinical response in people at UHR of psychosis. We report that currently there are no
reliable predictive markers that can be used to optimise treatment. We argue that there is an urgent need
for a better understanding of why some people at UHR of psychosis benefit from a certain treatment
whereas others do not. This information will help clinicians make more-effective treatment decisions,
and improve long-term clinical outcomes in this population.
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Psychosis is common, severely disabling and has
a major socioeconomic impact [1]. The onset of
the illness is typically preceded by a prodromal
phase that is characterised by the emergence of
‘attenuated’ psychotic symptoms; because only
about one-third of people with these symptoms
subsequently develop a psychotic disorder, this
phase is described as ultra-high risk (UHR) or at-
risk mental state (ARMS) of psychosis [2]. In the
past two decades, with the increasing appre-
ciation of the necessity for early intervention in
psychosis worldwide [3], a number of treatments
have been employed to delay or prevent the
onset of psychosis in people at UHR of psychosis.
These treatments include antipsychotic medi-
cation [4–6], nutritional supplements such as
omega-3 fatty acids [7] and psychological
treatment [8–13]. A recent meta-analysis924 www.drugdiscoverytoday.com
1359-6446/ 2015 The Authors. Psuggests that, based on evidence of very low to
moderate quality, these interventions appear to
be effective in delaying and even preventing the
onset of psychosis [14]. However there is great
individual variation in clinical response to
treatment among people at UHR of psychosis.
For example, although some respond well to
antipsychotic medication and report minimal
side-effects, others do not show any clinical
benefits and suffer from life-threatening side-
effects such as weight gain, hyperlipidemia,
movement disorders and agranulocytosis [15].
Furthermore, persisting with treatment in people
who do not benefit from it could lead to a
worsening of symptoms [16]. One way of
addressing these challenges is to gain a better
understanding of why some people at UHR of
psychosis benefit from a certain intervention
whereas others do not, and then use thisublished by Elsevier Ltd. This is an open access article under the CC BYinformation to target delivery of intervention to
the subgroup of patients most likely to benefit. In
the present systematic and quantitative report,
we therefore consider the current literature on
predictors of clinical response to available
treatments in this population (i.e. predictive
markers).
Literature search and article evaluation
We searched the PubMed database for extant
literature published online up to 16th February
2015, using the following search syntax: (marker
OR biomarker OR outcome OR response OR
prognosis OR prediction OR predictor OR pre-
dict) AND (at-risk mental state OR ultra-high risk
OR ultrahigh risk). This identified articles con-
taining the terms ‘marker’, ‘biomarker’, ‘outcome’,
‘response’, ‘prognosis’, ‘prediction’, ‘predictor’ or
‘predict’ in conjunction with ‘at-risk mental state’,-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.drudis.2015.03.003
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TABLE 1
Criteria for quality of evidence and effect size to grade predictive biomarkersAdapted, with permission, from [17].
Quality of evidence
An observation of a positive result (P < 0.05, corrected for multiple comparisons) Approximate
equivalence to drug
effects
Score
In an uncontrolled study – 0
In a study controlled for relevant extraneous variables (confounding, nuisance or effect modifiers)a,
that is, matched, restricted or adjusted for treatment, age, gender and (for genetic studies) ethnicity
Exploratory 1
In a study as above (grade 1), but with an explicit a priori intent to discover a precisely defined biomarker,
that is, with a given measure or modality, cut-off and direction of effect of biomarker and response
Phase I drug trial 2
In a study as above (grade 2), but designed with adequate power informed by previous positive studies
of the same biomarker, that is, replication in a larger cohort
Phase II drug trial 3
In at least two studies as above (grade 3) Phase III drug trial 4
Effect size
An observation of a statistically significant (positive) result (P < 0.05, corrected for multiple comparisons) Approximate
equivalence to drug
effectsa
Score
With estimate from studies with quality of evidence 1 – 0
With marginal effect (OR < 1.3, SMD < 0.2 or r < 0.1) – 1
With small effect size (OR = 1.3–1.5, SMD = 0.2–0.5 or r = 0.1–0.3) Effect of psychiatric
drugs on symptom
improvement
(median SMD = 0.41,
mean SMD = 0.49)
2
With medium effect size (possibly rivalling the drug effect; OR = 1.5–2.0, SMD = 0.5–0.8 or r = 0.3–0.5) Effect of
antipsychotic drugs
on acute symptom
improvement
(SMD = 0.51)
3
With large effect size (possibly exceeding the usual drug effect; OR > 2.0, SMD > 0.8 or r > 0.5) Effect of
antipsychotic drugs
on relapse
prevention
(SMD = 0.92)
4
Abbreviations: OR, odds ratio; SMD, standard mean difference; r, correlation coefficient.
a In genetic studies, this only needs to be applied in relation to the outcome variable, provided that genotypes are unknown (and thus naturally randomised) before subject inclusion, with
the exception of ethnicity which affects linkage disequilibrium patterns.
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medical subject heading (MeSH) terms such as
‘biological markers’ or ‘psychotic disorders’ in
any of the fields searchable in PubMed. We read
the abstracts and/or full text of the articles
yielded from this search with the aim of iden-
tifying those studies that had used a longitudinal
design to examine predictors of clinical response
to treatment. We then used a recently developed
two-dimensional scale [17] to rate the clinical
applicability of the predictive markers identified
in these studies. This scale, which is reported in
Table 1, was adapted from a biomarker rating
system proposed by Lassere [18] and is based on
quality of evidence (scored 1–4) and effect size
(scored 1–4). Quality of evidence is assessed
based on whether studies include a control
group, test-specific hypotheses, are prospec-
tively designed, appropriately powered and in-
dependently replicated; whereas effect size isassessed based on odds ratios. Predictive mar-
kers that reach a sum score of 6 (out of 8) are
considered clinically applicable (i.e. particularly
worthy of clinical consideration).
Systematic and quantitative review
observations
Our literature search identified 314 articles
published between 1990 and 2015. Careful ex-
amination of each article, however, revealed that
only two studies had investigated predictors of
clinical response to a given treatment and, as
such, were relevant to the present article. In the
first study, Morrison and colleagues carried out
exploratory analyses of the impact of pre-
treatment metacognitive and sociotropic scores
on clinical response to cognitive therapy [13];
these exploratory analyses were carried out in
the treatment group but not the control group
and did not detect any statistically significanteffects, resulting in a grade of 1 for quality of
evidence and for effect size. According to our
scoring system (Table 1) this yielded a sum score
of 0 that was well below our threshold for clinical
applicability. In the second study, Amminger and
colleagues examined biological and clinical
factors associated with clinical improvement
following 12 weeks of treatment with long-chain
omega-3 (v-3) polyunsaturated fatty acids
(PUFAs) [19]. An initial analysis using standard
univariate statistics revealed that higher levels of
erythrocyte membrane a-linolenic acid (ALA; the
parent fatty acid of the v-3 family) predicted
subsequent functional improvement in the
treatment group but not in the placebo group. A
subsequent analysis using multivariate machine
learning confirmed that baseline fatty acids
allowed prediction of response to treatment in
the v-3 PUFA group with high levels of sensi-
tivity, specificity and accuracy. According to ourwww.drugdiscoverytoday.com 925
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FIG. 1
From clinical applicability to clinical utility. Once longitudinal studies identify a predictive marker that is
clinically applicable (using the two-dimensional scale in Table 1), further randomised clinical trials (of
marker vs standard care) should be carried out so that additional factors such as cost of administration,
potential risks and side effects, inconvenience and delays associated with testing can be balanced and a
decision on its real-world clinical utility can then be made.
Adapted, with permission, from [17].
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rated as 1 on the basis that there was no a priori
hypotheses concerning the direction of the ef-
fect; and effect size was rated as 4 based on a
standard mean difference equal to 1.1. This
yielded a sum score of 4 that was still below our
threshold for clinical applicability. The vast ma-
jority of the other articles were concerned with
nonspecific predictors of clinical outcome irre-
spective of treatment (n = 90), reported cross-
sectional rather than longitudinal comparisons
(n = 82), reviewed the existing literature without
presenting new data (n = 64), tested the main
effect of a treatment of interest without con-
sidering predictors of clinical response (n = 14)
or focused on other clinical groups (n = 32). See
Supplementary material available online for the
full list of searched articles divided by category.
Differentiating between prognostic and
predictive markers
Whereas previous reviews on clinical outcome in
people at UHR of psychosis have focused on
predictors of clinical outcome irrespective of
treatment (i.e. prognostic markers) [20], here we
examine the existing evidence for predictors of
clinical response to available treatments (i.e.
predictive markers). Our systematic and quan-
titative report indicates that at present we have
no clinically applicable predictive markers that
could be used to optimise treatment of this
population. This conclusion is consistent with
our previous systematic and quantitative review
of predictors of treatment response in people
with already established psychosis [17], where
we found only one predictive biomarker meet-
ing our criteria for clinical applicability (the HLA-
DQB1 6672G>C SNP which predicts side-effects
of clozapine administration). The current paucity
of predictive markers, in UHR and established
psychosis, might be explained by the method-
ological challenges of differentiating between
predictors of clinical response to a given treat-
ment of interest and nonspecific predictors of
clinical outcome. However, although there is no
doubt that designing a study that differentiates
between these two types of markers requires
careful consideration, this is by no means
impossible based on lessons from other areas of
medicine [21]. In particular, a pre-treatment
variable can be considered a predictor of clinical
response if it can be shown to have an interactive
effect with treatment on clinical outcome; in
other words, the effect of treatment on indi-
vidual subjects must depend on this pre-treat-
ment variable [22]. By contrast, a pre-treatment
variable should be considered a nonspecific
predictor of clinical outcome if it has a main926 www.drugdiscoverytoday.comeffect on clinical outcome but no interactive
effect with treatment; that is, the effect of
treatment on individual subjects does not
depend on this pre-treatment variable [22].
Following this methodological framework [22],
future studies should be able to differentiate
between predictive (i.e. treatment-specific) and
prognostic (i.e. treatment-nonspecific) markers,
in people at UHR of psychosis and those who
have developed the illness.
From clinical applicability to clinical utility
Although we have used a two-dimensional scale
to rate the clinical applicability of predictive
biomarkers in people at UHR of psychosis, we
note that clinical applicability per se does not
assure real-world clinical utility. This is because
the clinical utility of a predictive marker depends
not only on the effect size but also on the clinical
context: a test with a small effect size that would
prevent a fatal side-effect is more useful than
one with a large effect that would prevent a
minor rash [17]. In addition, clinical utility is
dependent on the ability of a marker to generate
a ‘divergent prediction’: a test that is highlyaccurate at predicting clinical response to a
given treatment is not particularly useful if there
are no alternative treatments [23]. A number of
indices have been proposed in recent years with
the aim of encapsulating the clinical utility of a
marker in real-world clinical practice. For
example, the number-needed-to-assess (NNA)
refers to the number of individuals who need to
be screened to result in one additional positive
outcome [24]; this index was adapted from a well
established measure of the impact of a new
treatment known as number-needed-to-treat
(NNT) [25]. Although these indices provide a
better proxy of clinical utility than traditional
statistical measures, it remains challenging to
encapsulate the clinical utility of a marker into a
simple and universal formula owing to the large
number of factors such as cost of administration,
potential risks and side effects, inconvenience
and delays associated with testing (Fig. 1).
Concluding remarks
Here, we show that, at present, a clinician has no
way of predicting whether a person at UHR of
psychosis will or will not benefit from a given
Drug Discovery Today  Volume 20, Number 8 August 2015 PERSPECTIVE
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a better understanding of why some people at
UHR of psychosis benefit from a certain treat-
ment whereas others do not. This information
will help clinicians make more-effective treat-
ment decisions in their everyday clinical practice.
For example, those people at UHR of psychosis
who are likely to benefit could be offered psy-
chological treatment, whereas those who are
unlikely to benefit could be offered alternative
interventions, such as fish oil. Such stratification
of treatment would result in better long-term
clinical outcome and quality of life among
people at increased risk of developing psychosis.
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